Inactivation of the retinoblastoma tumor suppressor in humans (RB) and in mice (Rb) facilitates neoplastic progression. To a large part, pRB regulates growth by repressing E2F/DP famil) complexes, a subset of which when free, stimulates cell cycle progression. Instead, pRB stimulates differentiation by regulating transcription factors responsible for specific differentiation programs (e.g., activation of MyoD, C/EBP, CBFA1). Yet, loss of pRB does not compromise the development of all tissues, and germ-line RB or Rb mutations lead to highly penetrant, tissue specific tumor predisposition. In vitro, the extent of Gl Cyclin/Cdk-mediated phosphorylation governs the ability of pRB to restrain cell cycle progression; however, the recently demonstrated dispensability of Gl Cyclins and Cdks for the normal development of most tissues; raises the question of what is the """"""""wiring"""""""" that normally regulates the pRB/E2F/DP pathway in vivo. It is likely that the unique tumor suppressive function of pRB (among pRB family numbers) stems from its ability to coordinate growth inhibition with specific lineage commitment. Only by identifying the signals operating in vivo can we understand how loss of Rb disrupts the development of key tissues and facilitates tumorigenesis at specific sites. First, using our novel series of wildtype and mutant Rb promoter transgenics and a new Rb promoter knock-in allele, we will identify the activators and repressors that normally regulate the neuronal-specific expression of Rb and test the functional consequences of deregulating Rb expression in vitro and vivo (Aim 11. Second, we will define a requirement for the entire DP family and its individual family members (Dpi and Dpi) in cell cycle control and embryonic development through siRNA-mediated knockdown of DP family expression and the establishment of conditional Dpi and/or Dp2 knockout mice (Aim 2).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA079646-06A2
Application #
6968505
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Mietz, Judy
Project Start
1999-01-07
Project End
2010-05-31
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
6
Fiscal Year
2005
Total Cost
$337,319
Indirect Cost
Name
Columbia University (N.Y.)
Department
Biology
Type
Other Domestic Higher Education
DUNS #
049179401
City
New York
State
NY
Country
United States
Zip Code
10027
Yamasaki, Lili (2006) Modeling cell cycle control and cancer with pRB tumor suppressor. Results Probl Cell Differ 42:227-56
Agromayor, Monica; Wloga, Elzbieta; Naglieri, Benedetta et al. (2006) Visualizing dynamic E2F-mediated repression in vivo. Mol Cell Biol 26:4448-61
Kudo, Yasusei; Guardavaccaro, Daniele; Santamaria, Patricia G et al. (2004) Role of F-box protein betaTrcp1 in mammary gland development and tumorigenesis. Mol Cell Biol 24:8184-94
Wloga, Elzbieta H; Criniti, Vittoria; Yamasaki, Lili et al. (2004) Lymphomagenesis and female-specific lethality in p53-deficient mice occur independently of E2f1. Nat Cell Biol 6:565-7; author reply 567-8
Leung, Sandra W; Wloga, Elzbieta H; Castro, Alejandro F et al. (2004) A dynamic switch in Rb+/- mediated neuroendocrine tumorigenesis. Oncogene 23:3296-307
Yamasaki, Lili; Pagano, Michele (2004) Cell cycle, proteolysis and cancer. Curr Opin Cell Biol 16:623-8
Kohn, Matthew J; Leung, Sandra W; Criniti, Vittoria et al. (2004) Dp1 is largely dispensable for embryonic development. Mol Cell Biol 24:7197-205
Kohn, Matthew J; Bronson, Roderick T; Harlow, Ed et al. (2003) Dp1 is required for extra-embryonic development. Development 130:1295-305
Guardavaccaro, Daniele; Kudo, Yasusei; Boulaire, Jerome et al. (2003) Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev Cell 4:799-812